Intacept

Etanercept is a recombinant fusion protein comprising the extracellular ligand-binding domain of the human tumor necrosis factor receptor p75 fused to the Fc portion of human immunoglobulin G1, functioning as a competitive inhibitor of tumor necrosis factor alpha (TNF-α) and TNF-β to attenuate inflammatory signaling in autoimmune conditions.[1][2] Developed by Immunex Corporation and marketed under the brand name Enbrel, it received initial U.S. Food and Drug Administration approval in November 1998 for reducing signs and symptoms of moderately to severely active rheumatoid arthritis, marking the advent of TNF-targeted biologic therapies in rheumatology.[3][4] Subsequent approvals expanded its indications to include polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and chronic moderate to severe plaque psoriasis, often demonstrating efficacy in inhibiting radiographic progression of joint damage when used alone or with methotrexate.[5][6] Administered via subcutaneous injection, etanercept binds soluble TNF without inducing complement-mediated lysis or antibody-dependent cellular cytotoxicity against TNF-expressing cells, distinguishing its mechanism from monoclonal antibodies.[1][7] Amgen acquired Immunex in 2002, integrating etanercept into its portfolio as a high-volume biologic with sustained clinical use, though treatment requires monitoring for serious infections, tuberculosis reactivation, and malignancies due to TNF inhibition's